No-biopsy Approach in Celiac Disease: Cut-off Points for IgA Anti-tissue Transglutaminase Assays
Key facts
- Where
- Barcelona, Lugo, Madrid, and Terrassa, SpainSee the 6 sites
Where in Spain
- Hospital Sant Joan de DéuBarcelona, SpainContact: Elisabet PoyatosTaking people
- Hospital Universitario Lucus AugustiLugo, SpainContact: Julia María Cabo del RiegoTaking people
- Hospital Ramón y CajalMadrid, SpainContact: Garbiñe Roy AriñoTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainContact: María José Martínez BecerraTaking people
- Hospital Universitario La PazMadrid, SpainContact: Marta Molero-Luis, DrTaking people
- Hospital Mutua TerrassaTerrassa, SpainContact: Albert Martin CardonaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Instituto de Investigación Hospital Universitario La Paz
- Trial code
- NCT05983978
- Record updated
- 6 August 2025
- Original description
The main objective of this multicenter and observational study is to define the optimal threshold of different commercially available IgA anti-transglutaminase (tTG-IgA) antibody assays for celiac disease diagnosis (CD) avoiding the need for an intestinal biopsy.Read full original descriptionShow less
No-biopsy Approach for the Diagnosis of Celiac Disease: Definition of Cut-off Points for Different IgA Anti-tissue Transglutaminase Assays
The main objective of this multicenter and observational study is to define the optimal threshold of different commercially available IgA anti-transglutaminase (tTG-IgA) antibody assays for celiac disease diagnosis (CD) avoiding the need for an intestinal biopsy.
The main questions to be answered are:
* Is the anti-tTG-IgA titer cut-off above 10 times the upper limit of normal (ULN) useful in all anti-tTG IgA assays? * Is the diagnostic performance of the newly defined cut-offs of anti-tTG-IgA the same in all the evaluated assays? * Is the dynamic of the anti-tTG-IgA levels after the introduction of the gluten-free diet (GFD) similar across the different assays included in the study?
This is a prospective multicenter study that will enroll pediatric and adult patients with new-onset CD during the years 2023 and 2024. Serum from these patients will be collected for the determination of anti-tTG-IgA according to the local methodology (participating hospital) and by the anti-tTG IgA assays most commonly used in our country, which will be centralized in the same reference center (Hospital Universitario La Paz).
Inclusion: Patients, on gluten-containing diet, with TGt-IgA antibodies > Upper Limit of Normal (ULN) and intestinal biopsy confirming celiac disease (CD); Patients with TCRγδ+ >10% combined with decrease NK-like intraepithelial lymphocytes in the intestinal epithelium; Paediatric patients who meet ESPGHAN criteria (TGt-IgA antibodies >10xULN) without duodenal biopsy performed.
Exclusion: Patients with malignancy; Recruited patients whose remaining serum cannot be sent to the reference centre, whose biopsies are of poor quality or who nod not sign the informed consent from; Patients already diagnosed with CD; Patients who refused duodenal biopsy; Patients with primary or secondary immunodeficiencies.